TUNE-401 Epigenetic Silencing Clinical PoC
Tune Therapeutics presented the first clinical proof-of-concept data for CRISPR-based epigenetic silencing in humans, demonstrating deep, dose-dependent and durable reductions in HBV biomarkers with TUNE-401 in chronic hepatitis B patients.
